Cotinine Assay is a noninvasive urine test that measures levels of cotinine,
a major metabolite of nicotine, to determine whether second-hand smoke has impacted
the system of the exposed individual. This test is particularly useful for persons
exposed to environmental smoke on a regular basis.
Increasingly,
overwhelming evidence is accumulating about the serious health risks associated
with exposure to second-hand smoke.
Environmental
tobacco smoke is classified as a Class A carcinogen. Because of its lower burning
temperature, sidestream smoke from a burning substance such as a cigarette actually
contains higher concentrations of toxins such as nicotine than inhaled smoke.
Healthy nonsmokers exposed to environmental smoke have a dramatically increased
risk of lung and nasal cancer, as well as ischemic heart disease and stroke.
Passive exposure to tobacco metabolites also raises the likelihood of developing
chronic respiratory diseases, and may exacerbate already existing health conditions
such as asthma or cystic fibrosis.
Self-reports
about the smoking habits of family members/friends or about the personal/work
environment cannot always accurately reflect the actual health impact of tobacco
smoke on exposed individuals. Cotinine testing provides practitioners with a
more accurate clinical benchmark to gauge the potential health consequences
of second-hand smoke exposure.
Children
with parents who smoke, and who present with recurrent health problems such
as chronic ear infections, colds or asthma, are strongly recommended for cotinine
testing. High levels of cotinine in the child's urine indicate that the parent's
smoking is affecting the child's health. Environmental smoke has been linked
with learning disorders in children.
Urinary
cotinine is also useful for evaluating exposure status in pregnant women exposed
to smoke. Studies have shown that cotinine may be passed on through breast milk
to infants by mothers who smoke. The test can also gauge the effects of occupational
exposure to smoke or industrial pollutants.
The
Cotinine Assay requires the collection of one random urine sample. Test results
help practitioners and patients better understand the actual health impact from
second-hand smoke, and to monitor the effectiveness of strategies designed to
reduce exposure.
FEES
INCLUDE:
Kit:
$14.95, Great Smokies Performance of Test: $60.00, Dr Banks follow-up consultation:
$125 (email/phone)